Dealbreaker on MSN4h
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...
Anemia Treatment Market Poised For Strong Growth, Expected To Hit USD 19.1 Billion By 2033
Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...
Yicai Global18h
US' FibroGen to Sell China Unit to AstraZeneca for USD160 Million
AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...